---
id: inbox-diabetes-expert-answer-review-sample-001-20260514
type: inbox-review
topic: diabetes
question_type: answer-review
language: zh
last_compiled_at: 2026-05-14
verification_status: processed
decision_grade: no
language_qa_status: light_checked
owner: codex
status: processed
---

# Expert Answer Review Sample 001, 2026-05-14

## Classification

`方案 + 内容处理`

This is sample `1` for the expert answer review prototype:

- prototype owner: [expert answer review prototype](../../../system/indexes/expert-answer-review-prototype-20260514.md)
- original answer: `/Users/jiawei/Downloads/feline-diabetes-ask-the-vault-answer.md`
- reviewer transcript: `/Users/jiawei/Desktop/问与答.md`
- expert lens: Jacquie Rand, feline diabetes clinical research / remission / endpoint design

## Original Answer Summary

The Ask the vault answer said feline diabetes endpoints differ from mouse or monkey models because cats require multi-layer clinical observation:

- glycemic control
- fructosamine / serum glucose
- insulin dependence state
- remission monitoring
- SGLT2 safety monitoring
- body condition
- neuropathy and pathology-supported chronic complications

The answer cited `src-diabetes-004`, `src-diabetes-005`, and `src-diabetes-011`, and used `llm_inference` for several broader comparisons.

## Expert Review Signal

The external review was useful because it did not merely polish wording.

It converted the answer into an endpoint-design critique:

`the answer is directionally right, but too flat; it should distinguish baseline efficacy endpoints, conditional remission endpoints, safety endpoints, body-condition endpoints, and complication/exploratory endpoints`

## Findings

| # | Finding | Review Type | System Read | Decision |
|---|---|---|---|---|
| 1 | "Remission as core endpoint" is too broad without scenario qualification. | endpoint hierarchy | Existing source `src-diabetes-007` supports remission visibility and boundary control, not universal endpoint primacy. | partial-promote |
| 2 | Non-insulin dependence and true remission need stronger separation, especially with SGLT2 therapy. | wording downgrade | Existing cards already warn that insulin discontinuation, drug-controlled state, and remission are not interchangeable. | promote wording guardrail |
| 3 | Glycemic control needs layers: short-term, medium-term, dynamic/home monitoring, and clinical signs. | endpoint hierarchy | Current endpoint handbook says not to collapse glucose, fructosamine, insulin needs, and clinical response, but can be more operational. | hold for next endpoint precision batch |
| 4 | Neuropathy is important, but not a universal core endpoint. | wording downgrade | Existing `src-diabetes-004`/`018` support complication reality; endpoint page already calls it a complication branch. | no canonical change needed now |
| 5 | SGLT2 safety needs more concrete adverse-event endpoints. | source gap / endpoint hierarchy | Existing `src-diabetes-011` plus regulatory cards contain the right boundary; exact label monitoring details belong to label-control pages. | hold for SGLT2 label precision |
| 6 | The "40% obesity" figure needs source/location restraint if used in formal answer text. | wording downgrade | Existing `src-diabetes-005` quotes it, but formal outputs should avoid using it as an unqualified universal prevalence. | hold, add to future output QA |
| 7 | Cat versus mouse/monkey comparison was too generic. | scenario specificity | Comparative model claims need purpose-specific wording: mechanism model, translational model, or companion-animal clinical endpoint. | hold for future comparative-model sample |

## Immediate Write-Back

Apply one conservative canonical change:

- update diabetes endpoint/remission wording so remission is not framed as a universal core endpoint
- preserve remission as high-value and structurally important
- keep non-insulin dependence separate from formal remission

Target:

- [diabetes endpoint handbook](../../../topics/diabetes/endpoint-handbook.md)
- [diabetes remission boundary memo](../../../system/indexes/diabetes-remission-boundary-memo.md)

## What Not To Say

Do not say:

- remission is always the core endpoint
- SGLT2-controlled cats are in remission because they are not using insulin
- neuropathy should be a routine primary endpoint in every feline diabetes study
- a single obesity prevalence number is globally stable without population/source context
- mouse or monkey diabetes models are simply less clinical or less valid

## Query/Test Implication

This sample suggests a future regression question:

`猫糖尿病项目里，哪些观察指标能作为核心终点，哪些只能作为次要或探索性终点？`

Expected answer behavior:

- ask or infer scenario when possible
- lead with glycemic control and clinical signs as base endpoints
- treat remission as conditional/high-value, not universal
- separate insulin independence from drug-free remission
- place neuropathy under complication endpoints
- place SGLT2 adverse events under safety endpoints

Do not add the test yet. One sample is not enough to freeze a new expert-review test suite.

## Codification Read

Stable enough for final workflow?

`no`

Reason:

- only `1` sample completed
- useful pattern is visible, but still needs `2-9` more Ask the vault answer reviews
- final owner should be chosen after seeing whether failures are mostly prompt, routing, topic-page compression, or source-depth gaps
